MarketBeat on MSN
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF holds them all
After a lackluster first half of 2025, healthcare stocks staged a comeback, posting the best performance among the 11 S&P 500 ...
Nearly 2.2 million patients were prescribed a GLP-1 RA between January 2019 and December 2025, according to the study.
Tirzepatide doesn’t necessarily wear off after 5 days. The half-life of tirzepatide is 5 days, meaning the amount you have in ...
Public Advisory - Thinking about buying GLP-1 drugs like Ozempic or Mounjaro? Beware of fake or unauthorized products ...
Indianapolis-based Eli Lilly and Co. reported third-quarter results Thursday that easily topped Wall Street expectations, with revenue of $17.6 billion—up 54% from a year ago, driven by huge growth in ...
Eli Lilly is suing two pharmacies for compounding Zepbound and Mounjaro, claiming the companies are skirting the Food and Drug Administration's ban on the practice and luring people away from Lilly's ...
Eli Lilly (LLY) downgraded to Sell as obesity-drug competition and pricing pressure rise; stretched valuation boosts downside ...
Once exclusively a treatment for diabetes, GLP-1 medications have gone mainstream — forcing restaurants to adjust to changing ...
"I want to be here for a long time, and I want to look my best," the the actress said of using a GLP-1 to combat menopause ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results